Και οι δύο λάθος κάναμε.
Minoxidil was developed in the late 1950s by the
Upjohn Company (later became part of
Pfizer) to treat
ulcers. In trials using dogs, the compound did not cure ulcers, but proved to be a powerful vasodilator. Upjohn synthesized over 200 variations of the compound, including the one it developed in 1963 and named minoxidil.
[20] These studies resulted in
FDA approving minoxidil (with the trade name 'Loniten') in the form of oral
tablets to treat
high blood pressure in 1979.
[21]
Εγω ξερω πολυ καλα τι λεω. Εσυ εισαι ημιμαθης και κανεις λαθος και συνεχιζεις μεχρι τωρα. Γιατι παρελειψες την αμεσως επομενη παραγραφο?
Hair growth
When Upjohn
received permission from the FDA to test the new drug as medicine for hypertension they approached Charles A. Chidsey MD, Associate Professor of Medicine at the
University of Colorado School of Medicine.
[20] He conducted two studies,[22][23] the second study showing unexpected hair growth. Puzzled by this side-effect, Chidsey consulted Guinter Kahn and discussed the possibility of using minoxidil for treating hair loss.
Kahn along with his colleague Paul J. Grant MD obtained a certain amount of the drug and conducted their own research, apparently without notifying Upjohn or Chidsey.
[24] The two doctors had been experimenting with a 1% solution of minoxidil mixed with several alcohol-based liquids.
[25] They tried to patent the drug for hair loss prevention, but found that Upjohn had already done this. A decade-long trial between Kahn and Upjohn ended with Kahn's name included in a consolidated patent (U.S. #4,596,812 Charles A Chidsey, III and Guinter Kahn) in 1986 and royalties from the company to both Kahn and Grant.
[24]
Meanwhile the effect of minoxidil on hair loss prevention was so clear that in the 1980s physicians were prescribing Loniten off-label to their balding patients.[21]
In August, 1988, the FDA finally approved the drug for treating baldness in men
[21][25] under the trade name 'Rogaine' (FDA rejected Upjohn's first choice, Regain, as misleading
[26]). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head".
[26]
Η μινοξιδιλη χρησιμοποιηθηκε στα σκυλια για την υπερταση, οχι για την τριχοπτωση. Στους ανθρωπους παρατηρηθηκε σαν παρενεργεια η αυξηση της τριχοφυιας. Ποσες αλλες φορες θες να το ακουσεις για να το καταλαβεις?